Posted on October 1, 2019 by Sitemaster
From a report presented by Hussain yesterday at the annual meeting of the European Society for Medical Oncology (ESMO) we gained detailed insight into the results of the PROfound trial of olaparib (Lynparza), which had been said to be positive last August. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, gene, Lynparza, mCRPC, metastatic, mutation, olaparib | 3 Comments »
Posted on October 8, 2018 by Sitemaster
A newly published paper in the journal Prostate Cancer and Prostatic Diseases has explored the above question based on data from the Johns Hopkins active surveillance (AS) cohort of men with initially low- or very low-risk prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, association, enzyme, gene, PTEN, surveillance | 4 Comments »
Posted on January 10, 2018 by Sitemaster
Data from the ongoing, prospective IMPACT study has shown that PSA velocity is not predictive of risk for a positive prostate cancer biopsy result in men who are carriers of the BRCA2 gene. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: BRCA1/2, gene, hereditary, PSA, risk, status, velocity | 1 Comment »
Posted on September 22, 2017 by Sitemaster
A new paper by an international group of researchers from several different centers has maybe identified a new way to differentiate accurately between indolent and aggressive forms of prostate cancer at time of initial diagnosis. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: aggressive, expression, EZH2, gene, indolent, risk, TOP2A | 1 Comment »
Posted on August 30, 2017 by Sitemaster
Within the past few hours, the US Food and Drug Administration (FDA) has approved the very first form of chimeric antigen receptor (CAR) T-cell therapy for the treatment of cancer — and this is also the first true form of gene therapy to be made available here in the US. … READ MORE …
Filed under: Uncategorized | Tagged: CAR-T, CTL019, gene, Kymriah, therapy, tisagenlecleucel | 2 Comments »
Posted on August 9, 2017 by Sitemaster
A newly published and very detailed paper based on data from the PRACTICAL consortium now seems to have confirmed that taller men are at greater risk for high-risk prostate cancer than shorter ones (like your sitemaster). … READ MORE …
Filed under: Diagnosis, Risk | Tagged: gene, grade, growth, Height, risk | 1 Comment »
Posted on May 5, 2017 by Sitemaster
A group at The Institute for Cancer Research and The Royal Marsden Hospital in the UK — along with other European colleagues — has come up with a new, relatively low-cost test that seems to be able to identify men with advanced forms of prostate cancer who are more or less likely to respond well to treatment with drugs like abirateone acetate and enzalutamide. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: androgen, gene, receptor, resistance, test | 4 Comments »